Get the right peptide and research liquid for all your research needs. Whether you’re a Biomolecular Engineering student studying amino acids and compounds, or a professional Chemical Engineer working on a next-level research project, Rasa Research is the competitive brand you’re looking for.

Our wide selection of laboratory quality peptides includes ghrp-6, ghrp-2, pt-141, ipamorelin, igf-1 lr3, bremelanotide, aicar, melanotan ii, and many more.

Our research liquids include tamoxifen, clenbuterol, anastrozole, pramipexole, tadalafil, letrozole, clomiphene, LGD-40333, MK-2866, MK-677, RAD140, YK-11 and more.

What is Anastrozole?

Anastrozole, sold under the brand name Arimidex among others, is a medication used in addition to other treatments for breast cancer.[6][7] Specifically it is used for hormone receptor-positive breast cancer.[7] It has also been used to prevent breast cancer in those at high risk.[7] It is taken by mouth.[7]

Common side effects of anastrozole include hot flashes, altered mood, joint pain, and nausea.  Severe side effects include an increased risk of heart disease and osteoporosis.[7] Use during pregnancy may harm the baby.[7] Anastrozole is in the aromatase-inhibiting family of medications.[7] It works by blocking the production of estrogens in the body, and hence has antiestrogenic effects.

Anastrozole was patented in 1987 and was approved for medical use in 1995. It is on the World Health Organization’s List of Essential Medicines.[10] Anastrozole is available as a generic medication.  In 2019, it was the 176th most commonly prescribed medication in the United States, with more than 3 million prescriptions.

Early puberty:
Anastrozole is used at a dosage of 0.5 to 1 mg/day in combination with the antiandrogen bicalutamide in the treatment of peripheral precocious puberty, for instance due to familial male-limited precocious puberty (testotoxicosis) and McCune–Albright syndrome, in boys.

Interactions:
Anastrozole is thought to have clinically negligible inhibitory effects on the cytochrome P450 enzymes CYP1A2, CYP2A6, CYP2D6, CYP2C8, CYP2C9, and CYP2C19. As a result, it is thought that drug interactions of anastrozole with cytochrome P450 substrates are unlikely.[4] No clinically significant drug interactions have been reported with anastrozole as of 2003.

Anastrozole does not affect circulating levels of tamoxifen or its major metabolite N-desmethyltamoxifen. However, tamoxifen has been found to decrease steady-state area-under-the-curve levels of anastrozole by 27%.[3][2] But estradiol levels were not significantly different in the group that received both anastrozole and tamoxifen compared to the anastrozole alone group, so the decrease in anastrozole levels is not thought to be clinically important.

Anastrozole is a nonsteroidal benzyltriazole.[3][4] It is also known as α,α,α’,α’-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile.[1] Anastrozole is structurally related to letrozole, fadrozole, and vorozole, with all being classified as azoles.

Research:

Anastrozole is surprisingly ineffective at treating gynecomastia, in contrast to selective estrogen receptor modulators like tamoxifen.

Anastrozole was under development for the treatment of female infertility but did not complete development and hence was never approved for this indication.

An anastrozole and levonorgestrel vaginal ring (developmental code name BAY 98-7196) was under development for use as a hormonal contraceptive and treatment for endometriosis, but development was discontinued in November 2018 and the formulation was never marketed.

Anastrozole increases testosterone levels in males and has been studied as an alternative method of androgen replacement therapy in men with hypogonadism. However, there are concerns about its long-term influence on bone mineral density in this patient population, as well as other adverse effects.

Buy USA Made Research Liquids and Peptides Online from Rasa Research.